Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

BMC Psychiatry

Joo-Cheol Shim³  Bernard A Fischer²  William R Keller⁴  Dale Warfel⁴  Robert W Buchanan⁴  Robert P McMahon⁴  Stephanie Feldman⁴  Faith B Dickerson¹  Kelli M Sullivan⁴  Amber K Earl⁴  Heidi J Wehring⁴  Deanna L Kelly⁴ 

[1]Sheppard and Enoch Pratt Hospital, Baltimore, Maryland, USA

[2]VA Capital Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), Baltimore, Maryland, USA

[3]Department of Psychiatry and Clinical Trial Center, Busan Paik Hospital, Inje University, Busan, South Korea

[4]School of Medicine, Maryland Psychiatric Research Center, University of Maryland Baltimore, Baltimore, Maryland, USA

关键词: Aripiprazole;    Osteoporosis;    Sexual dysfunction;    Clinical trial;    Galactorrhea;    Amenorrhea;    Prolactin;    Women;   

Others  :  1123979
DOI  :  10.1186/1471-244X-13-214

 received in 2013-04-18, accepted in 2013-08-07,  发布年份 2013

【 摘 要 】

Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction and bone loss. These side effects increase risk of antipsychotic nonadherence and suicide and pose significant problems in the long term management of women with schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed to address these significant side effects and help the field better personalize the treatment of women with schizophrenia.

【 授权许可】

   
2013 Kelly et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Beumont PJ, et al.: The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea. J Psychiatry 1974, 124:413-419.
• [2]Haddad PM, Wieck A: Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64(20):2291-2314.
• [3]Hellewell JSE, Cantillon M: Antipsychotic tolerability: the attitudes and perceptions of medical professionals, patients and caregivers towards the side effects of antipsychotic therapy. Eur Neuropsychopharmacol 1998, 8:S248.
• [4]Bushe C, Shaw M: Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 2007, 21(7):768-773.
• [5]Buchanan RW, et al.: The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010, 36(1):71-93.
• [6]Brugnoli R, et al.: Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study. BMC Psychiatry 2012, 12:83. BioMed Central Full Text
• [7]Frantz AG: Prolactin. N Engl J Med 1978, 298(4):201-207.
• [8]Comparelli A, et al.: Emotion recognition impairment is present early and is stable throughout the course of schizophrenia. Schizophr Res 2013, 143(1):65-69.
• [9]Liddle G, Liddle L: The biological principles of disease, in Endocrinology, S. LH and T. SO, Editors. Philadelphia, PA: Saunders; 1981:653-754.
• [10]Marken PA, Haykal RF, Fisher JN: Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992, 11(10):851-856.
• [11]Lenton EA, et al.: Prolactin concentrations in normal menstrual cycles and conception cycles. Clin Endocrinol (Oxf) 1979, 10(4):383-391.
• [12]Melkersson K: Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2005, 66(6):761-767.
• [13]Bevan JS: Interpreting prolactin levels: implications for the management of large pituitary lesions. Br J Neurosurg 1991, 5(1):3-6.
• [14]Howes OD, et al.: Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry 2007, 68(3):361-367.
• [15]Jung DU, et al.: Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry 2006, 67(9):1391-1396.
• [16]Kinon BJ, et al.: Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006, 31(5):577-588.
• [17]Kinon BJ, et al.: Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003, 28(Suppl 2):55-68.
• [18]Jung DU, et al.: The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol 2005, 25(6):613-615.
• [19]Freeman ME, et al.: Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000, 80(4):1523-1631.
• [20]Gudelsky GA: Tuberoinfundibular dopamine neurons and the regulation of prolactin secretion. Psychoneuroendocrinology 1981, 6(1):3-16.
• [21]Tuomisto J, Mannisto P: Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 1985, 37(3):249-332.
• [22]Keks NA, Copolov DL, Singh BS: Abnormal prolactin response to haloperidol challenge in men with schizophrenia. Am J Psychiatry 1987, 144(10):1335-1337.
• [23]Meltzer HY, Fang VS: The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976, 33(3):279-286.
• [24]Smith S, et al.: The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002, 22(2):109-114.
• [25]Turrone P, et al.: Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002, 159(1):133-135.
• [26]Tran PV, et al.: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997, 17(5):407-418.
• [27]Crawford AM, Beasley CM Jr, Tollefson GD: The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997, 26(1):41-54.
• [28]Markianos M, Hatzimanolis J, Lykouras L: Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci 2001, 251(3):141-146.
• [29]Arvanitis LA, Miller BG: Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997, 42(4):233-246.
• [30]Small JG, et al.: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Arch Gen Psychiatry 1997, 54(6):549-557.
• [31]King DJ, Link CG, Kowalcyk B: A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology (Berl) 1998, 137(2):139-146.
• [32]Borison RL, Arvanitis LA, Miller BG: ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. Seroquel. Study group. J Clin Psychopharmacol 1996, 16(2):158-169.
• [33]Grootens KP, et al.: Ziprasidone vs. olanzapine in recent onset schizophrenia and schizoaffective disorder: results of an 8-week double blind randomized controlled trial. Schizophr Bull 2011, 37(2):352-361.
• [34]Skopek M, Manoj P: Hyperprolactinaemia during treatment with paliperidone. Australas Psychiatry 2010, 18(3):261-263.
• [35]Kelly DL, Conley RR: A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006, 31(3):340.
• [36]Kane JM, et al.: Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007, 68(2):213-223.
• [37]Chan HY, et al.: Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry 2007, 68(1):29-36.
• [38]Aihara K, et al.: The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res 2004, 1003(1–2):9-17.
• [39]Barnes TR, Harvey CA: Psychiatric drugs and sexuality. In Sexual pharmacology. Edited by Riley AJ, Peet M, Wilson . Washington DC: Oxford Medical Publications; 1993:176-196.
• [40]Degen K: Sexual dysfunction in women using major tranquilizers. Psychosomatics: Journal of Consultation Liaison Psychiatry; 1982.
• [41]Dickson RA, Seeman MV, Corenblum B: Hormonal side effects in women: typical versus atypical antipsychotic treatment. J Clin Psychiatry 2000, 61(Suppl 3):10-15.
• [42]Ucok A, et al.: Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry 2007, 22(5):328-333.
• [43]Polishuk WZ, Kulcsar S: Effects of chlorpromazine on pituitary function. J Clin Endocrinol Metab 1956, 16(2):292-293.
• [44]Magharious W, Goff DC, Amico E: Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res 1998, 77(3):159-166.
• [45]Ghadirian AM, Chouinard G, Annable L: Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982, 170(8):463-467.
• [46]Chaffey JT, et al.: Total body irradiation as treatment for lymphosarcoma. Int J Radiat Oncol Biol Phys 1976, 1(5–6):399-405.
• [47]McIver B, Romanski SA, Nippoldt TB: Evaluation and management of amenorrhea. Mayo Clin Proc 1997, 72(12):1161-1169.
• [48]Gitlin M: Sexual dysfunction with psychotropic drugs. Expert Opin Pharmacother 2003, 4(12):2259-2269.
• [49]Rosenberg KP, et al.: A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther 2003, 29(4):289-296.
• [50]Fleischhacker WW, et al.: Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 1994, 382:11-15.
• [51]Perkins DO: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002, 63(12):1121-1128.
• [52]Burns T, et al.: Case management and assertive community treatment in Europe. Psychiatr Serv 2001, 52(5):631-636.
• [53]Olfson M, et al.: Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry 2005, 66(3):331-338.
• [54]Smith S: Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice. J Clin Psychopharmacol 2003, 23(3 Suppl 1):S27-S32.
• [55]Tamminga CA, et al.: Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 1997, 12(Suppl 1):S29-S35.
• [56]Pollack MH, Reiter S, Hammerness P: Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med 1992, 22(4):305-327.
• [57]Kelly DL, Conley RR: Sexuality and schizophrenia: a review. Schizophr Bull 2004, 30(4):767-779.
• [58]Pollack MH, Rosenbaum JF: Management of antidepressant-induced side effects: a practical guide for the clinician. J Clin Psychiatry 1987, 48(1):3-8.
• [59]Shen WW, Park S: Thioridazine-induced inhibition of female orgasm. Psychiatric Journal of the University of Ottawa 1982, 7(4):249-251.
• [60]Faiman C: Endocrine causes of impotence. Cleve Clin J Med 1993, 60(6):428-429.
• [61]Burke MA, McEvoy JP, Ritchie JC: A pilot study of a structured interview addressing sexual function in men with schizophrenia. Biol Psychiatry 1994, 35(1):32-35.
• [62]Nakonezny PA, Byerly MJ, Rush AJ: The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther 2007, 33(3):203-216.
• [63]Smith SM, O’Keane V, Murray R: Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002, 181:49-55.
• [64]Kelly D, et al.: Evaulating sexual function and prolactin levels in treatment-resistant schizophrenia. Schizophr Res 2001, 49:285.
• [65]Kleinberg DL, et al.: Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999, 19(1):57-61.
• [66]Sullivan G, Lukoff D: Sexual side effects of antipsychotic medication: evaluation and interventions. Hosp Community Psychiatry 1990, 41(11):1238-1241.
• [67]Segraves RT: Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989, 46(3):275-284.
• [68]DL K: The schizophrenic patient: the reproductive years and beyond. The Female Patient, OB-GYN Edition 2005, 30(8):22-31.
• [69]Moloney P, Elliott G, Johnson H: Experiences with priapism. J Urol 1975, 114(1):72.
• [70]Liu-Seifert H, et al.: Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat 2009, 5:47-54.
• [71]Kikuchi T, et al.: Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2012, 37(1):26-32.
• [72]Abraham G, et al.: Osteoporosis and schizophrenia: can we limit known risk factors? Biol Psychiatry 1995, 38(2):131-132.
• [73]Abraham G, Friedman RH, Verghese C: Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients. Biol Psychiatry 1996, 40(5):430-431.
• [74]Meaney AM, et al.: Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004, 184:503-508.
• [75]Abraham G, et al.: Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res 2003, 59(1):17-18.
• [76]O’Keane V, Meaney AM: Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005, 25(1):26-31.
• [77]Howard L, Kirkwood G, Leese M: Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007, 190:129-134.
• [78]Yarden PE, et al.: Adverse outcome of hip fractures in older schizophrenic patients. Am J Psychiatry 1989, 146(3):377-379.
• [79]Csermely T, et al.: Relationship between adolescent amenorrhea and climacteric osteoporosis. Maturitas 2007, 56(4):368-374.
• [80]Becker D, et al.: Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003, 64(7):761-766.
• [81]Meaney AM, O’Keane V: Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 2007, 93(1–3):136-143.
• [82]Bilici M, et al.: Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002, 112(7):817-828.
• [83]Graham SM, et al.: Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf 2011, 10(4):575-602.
• [84]Bosse P, et al.: Multiple neuroendocrine tumours in transgenic mice induced by c-kit-SV40 T antigen fusion genes. Oncogene 1997, 14(22):2661-2670.
• [85]Szarfman A, et al.: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006, 26(6):748-758.
• [86]Doraiswamy PM, et al.: Atypical antipsychotics and pituitary neoplasms in the WHO database. Psychopharmacol Bull 2007, 40(1):74-76.
• [87]MacMaster FP, et al.: Effect of antipsychotics on pituitary gland volume in treatment-naive first-episode schizophrenia: a pilot study. Schizophr Res 2007, 92(1–3):207-210.
• [88]Wang PS, et al.: Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002, 59(12):1147-1154.
• [89]Fava M, et al.: Psychosomatic aspects of hyperprolactinemia. Psychother Psychosom 1983, 40(1–4):257-262.
• [90]Kellner R, et al.: Hyperprolactinemia, distress, and hostility. Am J Psychiatry 1984, 141(6):759-763.
• [91]Buckman MT, Kellner R: Reduction of distress in hyperprolactinemia with bromocriptine. Am J Psychiatry 1985, 142(2):242-244.
• [92]Kelly DL, Conley RR: Evaluating sexual function in patients with treatment-resistant schizophrenia. Schizophr Res 2003, 63(1–2):195-196.
• [93]DL K: Treatment considerations in women with schizophrenia. J Womens Health 2006, 15:1132-1140.
• [94]Shim JC, et al.: Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007, 164(9):1404-1410.
• [95]Kim KS, et al.: Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002, 63(5):408-413.
• [96]Lee BH, Kim YK, Park SH: Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(4):714-717.
• [97]Byerly MJ, et al.: Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 2009, 107(2–3):218-222.
• [98]Chen CY, et al.: Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. Psychiatry Clin Neurosci 2011, 65(1):95-97.
• [99]Casey DE, et al.: Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003, 166(4):391-399.
• [100]Kaneda Y, et al.: Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia. Neuro Endocrinol Lett 2004, 25(1–2):135-140.
• [101]Haddad PM, Hellewell JS, Wieck A: Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol 2001, 15(4):293-295.
• [102]Kuloglu M, et al.: Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature. Arch Womens Ment Health 2010, 13(5):443-447.
• [103]McCue RE, et al.: Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006, 189:433-440.
• [104]Taylor D: Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence-based Mental Health 2007., 10(3)
• [105]Yuan HN, et al.: A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol 2008, 28(3):264-370.
• [106]Lee MS, et al.: Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci 2010, 64(1):19-27.
• [107]Cohn JB, et al.: Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment. Neuropsychobiology 1985, 13(4):173-9.
• [108]Cavallaro R, et al.: Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004, 65(2):187-90.
• [109]Andersohn F, Garbe E: Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord 2009, 24(1):129-33.
• [110]Wu RR, et al.: Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2012, 169(8):813-21.
• [111]Nunes LV, et al.: Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther 2012, 38(3):281-301.
• [112]Gopalakrishnan R, et al.: Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry 2006, 163(3):494-9.
• [113]Freeman B, Levy W, Gorman JM: Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. J Psychiatr Pract 2007, 13(2):120-4.
• [114]Anghelescu I, Wolf J: Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J Clin Psychiatry 2004, 65(9):1286-7.
• [115]Steinhagen CK: Normalization of prolactin with aripiprazole in a patient with psychotic depression and a comorbid pituitary microadenoma. Psychosomatics 2007, 48(4):350-1.
• [116]Potkin SG, et al.: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003, 60(7):681-90.
• [117]Kane JM, et al.: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002, 63(9):763-71.
• [118]McEvoy JP, et al.: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164(7):1050-60.
• [119]Kane JM, et al.: A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009, 70(10):1348-57.
• [120]D-U J, et al.: Adjunctive treatment with aripiprazole for risperidone-induced amenorrhea. in International Congress on Schizophrenia Research (ICOSR). Schiz Bull 2011, 37(suppl):307.
• [121]Yasui-Furukori N, et al.: Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 2010, 30(5):596-9.
• [122]Lim S, et al.: Possible increased efficacy of low-dose clozapine when combined with aripiprazole. J Clin Psychiatry 2004, 65(9):1284-5.
• [123]Ziegenbein M, Kropp S, Kuenzel HE: Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol 2005, 28(5):220-4.
• [124]Clarke LA, Lindenmayer JP, Kaushik S: Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry 2006, 67(4):675-6.
• [125]Ziegenbein M, Wittmann G, Kropp S: Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Investig 2006, 26(3):117-24.
• [126]Henderson DC, et al.: An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006, 113(2):142-7.
• [127]Karunakaran K, Tungaraza TE, Harborne GC: Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 2007, 21(4):453-6.
• [128]Abu-Tair F, Kopitz J, Bergemann N: Clozapine augmented with aripiprazole in 5 patients with schizophrenia. J Clin Psychopharmacol 2006, 26(6):669-71.
• [129]Rocha FL, Hara C: Benefits of combining aripiprazole to clozapine: three case reports. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(6):1167-9.
• [130]Mitsonis CI, et al.: Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006, 31:373-377.
• [131]Henderson DC, et al.: Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009, 29(2):165-9.
• [132]Fan X, et al.: Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013, 127(3):217-26.
• [133]Henderson DC, Doraiswamy PM: Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 2008, 69(Suppl 1):32-44.
• [134]O’Keane V: Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008, 22(2 Suppl):70-5.
• [135]American Psychiatric Association: Diagnostic criteria from DSM-IV-TR2000. Washington, D.C: The American Psychiatric Association; 2000:370.
• [136]First MB, et al.: User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I): Clinician Version. Washington, D.C.: American Psychiatric Press; 1997.
• [137]Berek JS, Adashi EY, Hillard PA: Novak’s gynecology. 159th edition. Baltimore, MD: Williams & Wilkins; 1996.
• [138]Wiegel M, Meston C, Rosen R: The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005, 31(1):1-20.
• [139]McGahuey CA, et al.: The arizona sexual experience scale (ASEX): reliability and validity. J Sex Marital Ther 2000, 26(1):25-40.
• [140]Derogatis LR, et al.: The female sexual distress scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002, 28(4):317-30.
• [141]Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep 1962, 10(79):812.
• [142]Andreasen NC: The scale for the assessment ofNegative symptoms (SANS). Iowa City: University of Iowa; 1983.
• [143]Addington D, Addington J, Maticka-Tyndale E: Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 1993, 22:39-44.
• [144]Guy W: ECDEU assessment manual for psychopharmacology, revised (DHEW Publication No. ADM 76–338). Rockville, MD: US Department of Health and Human Services; 1976.
• [145]Randolph C, et al.: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998, 20(3):310-9.
• [146]Buchanan RW, Carpenter WT: Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 1994, 182(4):193-204.
• [147]Ware JE: SF-36 health survey update. Spine (Phila Pa 1976) 2000, 25(24):3130-9.
• [148]Awad AG: Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993, 19(3):609-18.
• [149]Dupuy HJ, Wenger NK (Eds): Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Le Jacq, New York; 1984:170-183. Chapter 9
• [150]Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-9.
• [151]Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-6.